Semuloparin (AVE5026)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]

Route: SC
Extravasation: n/a

Patient drug information

No information available.


  1. Semuloparin (AVE5026) manufacturer's website
  2. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed